While the Farm Bill passing into Law affects the MJ industry positively in general including GBLX, here is a CBD play everybody MUST CHECK:
CVSI TTM Numbers (1 Year ago), Change & Trend Updated 5 Dec 2018 Stock Price: $4.63 50DSMA = $4.92 Average Price for last period between Q reports = $4.89 (69 days total)
Sales $41.26M. ($16.65M) 148% & rising Gross Profit $29.8M ($11.1M) 168% & rising GP Margin 72.22% (66.64%) 8.4% rising slow Net Income $7.6M (-13.2M) $20.8M & rising NI Margin 18.42% (NA) & rising Total Equity $25.7M ($15.3M) 68% & rising fast Shares Outstanding : 94.4M Far better than most in Industry SG&A % of Rev. 50%. (93%) Big & improving Debt: NONE Cash $11M ($2.3M) & rising fast Accounts Receivables: $2.5M & growing nicely in proportion to sales. Prepaid expenses: $1.85M & growing nicely in proportion to sales Working Capital $18.1M ($4.6M) 293% & rising fast Working Capital Ratio 7.1 (2.3) & rising fast FCF & Rate $12.1M 29.4%. (None) & rising fast
Other Numbers to consider: YTD FCF. $9.6M or 37%. Just WAO Q3’18 Net Profit Margin: 24.2% EPS: 8 cents PE = 57.9 a Fact Fwd Estimated EPS (Next 12 Months) = 20 to 22 cents or 163% (conservative pre FB) Fwd PE = ($4.63/$0.21) = 22 Market Cap = $437M Price to Sales Ratio = 10.6 MJ Industry big players = Well above 25 TTM ASGR (Average sequential growth rate Q/Q) = 25.5% (For 148% annual) TTM ASGR 1 year ago = 13.4% a big improvement. _____________________________________________________ Nutritional Outlook’s 2018 Best of the Industry Awards, Retail Brand/Product: CV Sciences
The Farm Bill & the FDA https://investorshub.advfn.com/boards/read_msg.aspx?message_id=145266066 ________________________________________________ CEO Joseph Dowling @ conference call Q2’18 Quote: Going forward, we are very optimistic about the growth potential for the hemp CBD product category. Industry forecasts estimate that the hemp CBD product category will reach nearly $1.6 billion by 2021(8.4 Times).
While not providing specific guidance, we believe our strong growth will continue, including our ability to generate profitable sales and cash flow. We believe the hemp CBD product category will continue to expand and our ability to grow as the market leader is well-positioned.
The first six months of 2018 have been a great start to the year for our company and we are confident in our ability to deliver a strong second-half to 2018 and believe that we can continue this growth momentum in 2019 and beyond.
Conferencie call Q3’18 Thank you, Debra good afternoon and thanks everyone for joining our call. Earlier today we filed our third quarter 10-Q and earnings press release and we are proud to announce another record financial quarter for the third straight quarter we achieved record revenue, gross profit, cash flow, adjusted EBITDA and net income. The momentum from the first half of 2018 has continued and we anticipate a strong finish for the remainder of the year.
__________________________________________________________ 2017 Hemp CBD market sales was $190M. CVSI sold $20.7M 2018 Estimate is $600M
_________________________________________ Drug development segment:
CV Sciences CFO, Joseph Dowling, discussed the Company's initial drug candidate (CVSI-007), How CVSI-007 works..
Catalysts for next 2 months : - Uplisting to the Nasdaq anytime - Hemp legalization in US (Highly possible) by end of year.
Other Catalysts: - potential for new products ( New trademarks on the work) - potential for new BIG RETAIL CHAIN additional stores - CV-007 IND (early 2019) _________________________________________________ Explaining the $4.00 Bid price, or the $2.00 - $3.00 minimum closing price for up-listing
* Currently traded companies qualifying solely under the Market Value Standard must meet the $50 million Market Value of Listed Securities and the applicable bid price requirement for 90 consecutive trading days before applying. ** To qualify under the closing price alternative, a company must have: (i) average annual revenues of $6 million for three years, or (ii) net tangible assets of $5 million, or (iii) net tangible assets of $2 million and a 3 year operating history, in addition to satisfying the other financial and liquidity requirements listed above.
Conclusion: It is clear that CVSI meets all the criteria under the "Equity Standard" requirements and qualifies under the closing price alternative. The minimum closing price must be $3.00 and does not need to wait 90 days.
News 
Market Data 
Discover 
